Side-by-side · Research reference
SelankvsThymosin α-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft11/40 cited
BPhase 3Reviewed8/39 cited
Selank
Anxiolytic + Cognitive · Russian Pharma
Intranasal · 2–3×/day during stress / cognitive demand
Thymosin α-1
Immune modulator · Approved (some countries)
SQ · 2× weekly · 6+ months for chronic indications
01Mechanism of Action
Parameter
Selank
Thymosin α-1
Primary target
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001
Pathway
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007
Downstream effect
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007
Origin
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001
Antibody development
—
—
02Dosage Protocols
Parameter
Selank
Thymosin α-1
Frequency
2–3× per day during stress
2× weekly (Mon/Thu typical)
Lower / starter dose
75 mcg / dose
0.8 mg per injection
Evidence basis
Human-mechanistic + Russian clinical trialsMedvedev 2007
Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007
Duration
10–14 day cycles, repeated as needed
6–12 months for chronic indications
Reconstitution
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Sterile water for injection per vial label
Timing
Morning + early afternoon preferred
No specific time
Half-life
Short (minutes plasma); CNS effect lasts ~3 hr
~2 hours plasma; tissue effect days
04Side Effects & Safety
Parameter
Selank
Thymosin α-1
Nasal irritation
Mild burning or congestion (transient)
—
Cognitive impairment
None — opposite effect (enhancement)
—
Allergic reaction
Rare hypersensitivity
—
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid — insufficient data
Avoid
Injection site reaction
—
Erythema, mild discomfort
GI symptoms
—
Rare nausea
Fatigue
—
Common during initial weeks
Fever / flu-like
—
Mild interferon-like response possible
Autoimmune
—
Theoretical risk; caution in active autoimmune disease
Cancer risk
—
No signal — used as adjuvant in oncology
Absolute Contraindications
Selank
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Thymosin α-1
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
- ·Concurrent immunosuppressant therapy (transplant patients)
Relative Contraindications
Selank
- ·Active autoimmune disease (theoretical via immunomodulation)
Thymosin α-1
- ·Active autoimmune disease
- ·Severe immunocompromised state without supervision
05Administration Protocol
Parameter
Selank
Thymosin α-1
1. Form
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.
2. Administration
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
2× weekly, e.g. Monday + Thursday.
4. Storage
Refrigerate after reconstitution; ≤30 days. Light-protected.
Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.
5. Caveat
Avoid co-administration with strong sedatives or other anxiolytics initially.
27–31G, 4–8 mm insulin syringe.